scholarly journals South Asian diabetic macular oedema treated with ranibizumab (ADMOR)—real-life experience

Eye ◽  
2015 ◽  
Vol 30 (1) ◽  
pp. 133-138 ◽  
Author(s):  
F Ghanchi ◽  
C A Hazel
Keyword(s):  
South Asian ◽  
Macular Oedema ◽  
Life Experience ◽  
Real Life ◽  
Diabetic Macular Oedema

scholarly journals Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema

2019 ◽  
Vol Volume 13 ◽  
pp. 2583-2590
Author(s):  
Tommi Karttunen ◽  
Lasse Nummelin ◽  
Kai Kaarniranta ◽  
Kati Kinnunen
Keyword(s):  
Macular Oedema ◽  
Life Experience ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant

One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab

2020 ◽  
pp. 112067212092727
Author(s):  
Marko Lukic ◽  
Gwyn Williams ◽  
Zaid Shalchi ◽  
Praveen J Patel ◽  
Philip G Hykin ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Diabetic Retinopathy ◽  
Early Treatment ◽  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Foveal Thickness ◽  
Macular Volume ◽  
Central Foveal Thickness ◽  
The Mean

Purpose To assess visual and optical coherence tomography–derived anatomical outcomes of treatment with intravitreal aflibercept (Eylea®) for diabetic macular oedema in patients switched from intravitreal ranibizumab (Lucentis®). Design Retrospective, cohort study. Participants Ninety eyes (of 67 patients) receiving intravitreal anti–vascular endothelial growth factor therapy were included. Methods This is a retrospective, real-life, cohort study. Each patient had visual acuity measurements and optical coherence tomography scans performed at baseline and 12 months after the first injection of aflibercept was given. Main Outcome Measures We measured visual acuities in Early Treatment Diabetic Retinopathy Study letters, central foveal thickness and macular volume at baseline and at 12 months after the first aflibercept injection was given. Results Ninety switched eyes were included in this study. The mean (standard deviation) visual acuity was 63 (15.78) Early Treatment Diabetic Retinopathy Study letters. At baseline, the mean (standard deviation) central foveal thickness was 417.7 (158.4) μm and the mean macular volume was 9.96 (2.44) mm3. Mean change in visual acuity was +4 Early Treatment Diabetic Retinopathy Study letters (p = 0.0053). The mean change in macular volume was −1.53 mm 3 in SW group (p = 0.21), while the change in central foveal thickness was −136.8 μm (p = 0.69). Conclusion There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Are the real‐life outcomes of using aflibercept in diabetic macular oedema comparable to the landmark studies?

2018 ◽  
Vol 97 (2) ◽  
Author(s):  
Aisling K. Higham ◽  
Muhammad I. Tahir ◽  
Kavita Gala ◽  
Georgios Verroiopoulos
Keyword(s):  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Life Outcomes ◽  
The Real

scholarly journals An open-source dataset of anti-VEGF therapy in diabetic macular oedema patients over four years & their visual outcomes

2019 ◽  
Author(s):  
Christoph Kern ◽  
Dun Jack Fu ◽  
Josef Huemer ◽  
Livia Faes ◽  
Siegfried K. Wagner ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Cohort Study ◽  
Open Source ◽  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Data Repository ◽  
Visual Outcomes ◽  
Anti Vegf ◽  
Observation Period

ABSTRACTPURPOSETo evaluate visual acuity (VA) outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in diabetic macular oedema (DMO).METHODSIn this retrospective cohort study, electronic medical records for all patients undergoing intravitreal injections (IVI) in a tertiary referral centre between March 2013 and October 2018 were analysed. Treatment response in terms of visual acuity outcomes were reported for all eyes over a 4-year observation period.RESULTSOur cohort includes 2616 DMO eyes of 1965 patients over 48 months. Cox proportional hazards modelling identified injection number (hazard ratio [HR] = 1.18), male gender (HR = 1.13), and baseline VA (HR = 1.09) as independent predictors to reach a favorable visual outcome of more than 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Half of our cohort reached 70 letters 1.9 months after starting anti-VEGF therapy. Of those that reached 70 letters, 50% fell below 70 by 14.7 months.CONCLUSIONTo date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our dataset available on an open-source data repository as a resource for all clinical researchers globally.SYNOPSISUsing time-to-event analysis in patients receiving anti-VEGF for DMO: age, baseline visual acuity and injection number are independent predictors of visual outcomes.

OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study

2021 ◽  
pp. bjophthalmol-2021-319587
Author(s):  
Simon KH Szeto ◽  
Vivian W. K. Hui ◽  
Fang Yao Tang ◽  
Dawei Yang ◽  
Zi han Sun ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Serous Retinal Detachment ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Cystoid Macular Oedema ◽  
Anti Vegf ◽  
Central Subfield Thickness ◽  
Endothelial Growth Factors ◽  
Treatment Improvement ◽  
Sd Oct

Background/aimsTo determine whether a combination of baseline and change in spectral domain-optical coherence tomography (SD-OCT)-based biomarkers can predict visual outcomes in eyes with diabetic macular oedema (DMO) treated with antivascular endothelial growth factors (VEGF) injections.MethodsThis is a retrospective cohort study conducted in Hong Kong, China. 196 eyes with centre-involving DMO, who received anti-VEGF injections between 1 January 2011 and 30 June 2018 were recruited. Medical records of the participants were retrieved retrospectively, visual acuity (VA) at baseline, 6, 12 and 24 months and SD-OCT before initiation and after completion of anti-VEGF treatment were obtained. The SD-OCT images were evaluated for the morphology of DMO, vitreomacular status, presence of disorganisation of retinal inner layers (DRIL), sizes of intraretinal cysts, visibility of external limiting membrane (ELM), ellipsoid zone (EZ) and cone outer segment tip (COST) and the presence of hyper-reflective foci in retina or the choroid.ResultsThe presence of baseline DRIL, hyper-reflective foci in retina and disruption of ELM/EZ and COST were associated with worse baseline and subsequent VA up to 24 months after treatment. Improvement in DRIL (p=0.048), ELM/EZ (p=0.001) and COST (p=0.002) disruption after treatment was associated with greater improvement in VA at 12 months. Eyes with cystoid macular oedema (p=0.003, OR=8.18) and serous retinal detachment (p=0.011, OR=4.84) morphology were more likely to achieve at least 20% reduction in central subfield thickness.Conclusion and relevanceBaseline SD-OCT biomarkers and their subsequent change predict VA and improvement in vision in eyes with DMO treated with anti-VEGF injections. We proposed an SD-OCT-based system that can be readily used in real-life eye clinics to improve decision making in the management of DMO.

The AflibeRcept use in rEal life study for the treatment of diabetiC macular oedema In the French overseas territories: A 12 months follow-up Study - The RECIF Study

2021 ◽  
pp. 112067212110550
Author(s):  
Christophe Morel ◽  
John Conrath ◽  
Bruno Morin ◽  
Eric Parrat ◽  
Eleonora Zito ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
French Polynesia ◽  
Life Study ◽  
Life Management ◽  
French Overseas Territories ◽  
Overseas Territories ◽  
Referring Physicians

Purpose The incidence and severity of diabetes is particularly high in the French overseas territories (FOT). The RECIF study evaluated real life management of diabetic macular oedema (DME) treated by aflibercept in FOT. Methods A prospective, noncomparative, multicentric, non-interventional, study that evaluated functional and anatomical results of patients treated by aflibercept. Twelve retina specialists working in French Polynesia, La Reunion, Guadeloupe and Martinique participated in the study. Results 67 eyes of 57 patients were followed for 12 months. Average VA gain was 7.8 ETDRS letters. 29.9% of eyes gained at least 15 letters, 6% lost 15 letters or more. 67.2% of eyes achieved visual acuity of 70 letters or better. Average central retinal thickness decrease was 115.3 µm. The mean number of injections during the 1st year of treatment was 4.9. 69% of eyes had a loading dose of at least three-monthly injections. 3 eyes were switched to steroid injections during the follow-up for lack of efficacy. Conclusion This study confirmed the efficacy of intravitreal treatment of DME by aflibercept, in the French overseas territories. This evaluation of real-life management of DME underlines the importance of improvement of patient education and collaboration with referring physicians.

scholarly journals Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Matteo Fallico ◽  
Andrea Maugeri ◽  
Andrew Lotery ◽  
Antonio Longo ◽  
Vincenza Bonfiglio ◽  
...  
Keyword(s):  
Cataract Surgery ◽  
Real World ◽  
Macular Oedema ◽  
Meta Analysis ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Glaucoma Surgery ◽  
Fluocinolone Acetonide ◽  
Intravitreal Therapy ◽  
Mean Differences

AbstractWe conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean change of best corrected visual acuity (BCVA) at 24 months. Secondary outcomes were 36-month mean BCVA, mean central macular thickness (CMT) change, rates of eyes receiving supplementary intravitreal therapy, cataract surgery, intraocular pressure (IOP)-lowering drops and glaucoma surgery. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Nine real-world studies were included. The FAc implant yielded a significantly improved BCVA at 24 and 36 months (24-month MD = 4.52; 95% CI 2.56–6.48; 36-month MD = 8.10; 95% CI 6.34–9.86). These findings were comparable with the FAME study. The FAc implant yielded significantly reduced 24- and 36-month CMT. Pooled proportions of cataract surgery, IOP-lowering drops and glaucoma surgery were 39%, 27% and 3%, respectively, all lower than the FAME study. Pooled estimate of supplementary intravitreal therapy was 39%, higher than the 15.2% of the FAME study. This meta-analysis of real-world studies confirms favorable visual and anatomical outcomes following FAc insert for chronic DMO. In real-life studies more than one third of patients received supplementary intravitreal therapy, an issue that needs to be further explored.

Sign in / Sign up

Export Citation Format

Share Document